Completed
Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo
NCT05826028
- Conditions
- Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Chronic Disease, +10 more
- Locations
-
- Novartis Investigational Site Camperdown, New South Wales, Australia
- Novartis Investigational Site St Leonards, New South Wales, Australia